Three AstraZeneca patents ruled invalid in Australia

Drugs giant AstraZeneca has reported that the Federal Court of Australia has found three patents protecting the company's Crestor treatment to be invalid, after they were challenged by several pharmaceutical firms.

Drugs giant AstraZeneca has reported that the Federal Court of Australia has found three patents protecting the company's Crestor treatment to be invalid, after they were challenged by several pharmaceutical firms.

The court's decision only affects the patent in Australia and does not have an impact on the validity of patents related to Crestor in any other country.

Total sales of Crestor in Australia for 2012 were approximately $350m.

In a statement the group said: "AstraZeneca is disappointed in the court's decision to find these patents invalid. The company remains committed to defending its intellectual property protecting Crestor in Australia and is carefully reviewing this decision and evaluating all legal options at this time, which could include filing an appeal and seeking to maintain existing preliminary injunctions."

Of the patents, one was a formulation patent, the second was related to the use of rosuvastatin for treating heterozygous familial hypercholesterolemia (high cholesterol), and the third was related to the use of rosuvastatin for treating hypercholesterolemia.

The share price was up 0.47% to 3,022p by 09:05.

NR

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Here’s why you really should own at least some bitcoin
Bitcoin

Here’s why you really should own at least some bitcoin

While bitcoin is having a quiet year – at least in relative terms – its potential to become the default cash system for the internet is undiminished, …
16 Sep 2020
Will a second wave of Covid lead to another stockmarket crash?
Stockmarkets

Will a second wave of Covid lead to another stockmarket crash?

Can we expect to see another lockdown like in March, and what will that mean for your money? John Stepek explains.
18 Sep 2020
James Ferguson: How bad data is driving fear of a second wave of Covid-19
UK Economy

James Ferguson: How bad data is driving fear of a second wave of Covid-19

Merryn and John talk to MoneyWeek regular James Ferguson about the rise in infections in coronavirus and what the data is really telling us.
17 Sep 2020